Altimmune Inc

NASDAQ: ALT
$6.62
+$0.02 (+0.3%)
Closing Price on July 5, 2024

ALT Chart and Intraday Price

ALT Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG, MD, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 649.58M USD
Shares Outstanding 53,729,000
Altimmune Inc is a biopharmaceutical company based in Gaithersburg, Maryland, focusing on innovative treatments for obesity and liver diseases. Its leading product, pemvidutide, is a promising obesity and non-alcoholic steatohepatitis treatment currently in Phase 2 trials. Additionally, Altimmune is developing HepTcell, aimed at treating chronic hepatitis B virus infections, also in Phase 2 trials. Founded in 1997 and originally named Vaxin Inc., the company rebranded to Altimmune Inc in 2015, continuing its mission to address critical unmet medical needs.

ALT Articles

With a Fed Rate Hike Coming, Analysts Upgrade or Downgrade Sirius XM, Tencent Music and More
Thursday’s additional top analyst upgrades and downgrades were on Ally Financial, Altimmune, Capital One Financial, GoodRx, Leslie’s, PagSeguro Digital, Regions Financial, Sirius XM, StoneCo,...
Chris Lange
Published:

Wednesday Afternoon's Analyst Upgrades and Downgrades: Inovio Pharmaceuticals, McDonald's, VBI Vaccines, Wingstop and More
Wednesday afternoon's top analyst upgrades and downgrades included Inovio Pharmaceuticals, McDonald’s, Orchard Therapeutics, VBI Vaccines and Wingstop.
Chris Lange
Published:

Jim Cramer's Game Plan for This Week and the Start of Earnings Season
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
Chris Lange
Published:

Wednesday's Top Analyst Upgrades and Downgrades: Alphabet, Canopy Growth, Cinemark, Facebook, IMAX, Microsoft, Salesforce and More
Wednesday's top analyst upgrades and downgrades included Alphabet, Canopy Growth, Cinemark, Dick's Sporting Goods, Facebook, IMAX, Microsoft, Salesforce.com and SBA Communications.
Lee Jackson
Published:
Last Updated:

Intranasal COVID-19 Vaccine Shows Very Promising Preclinical Results
Altimmune has announced additional preclinical data in regards to its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.
Chris Lange
Published:

Top Analyst Upgrades and Downgrades: Allstate, Bed Bath & Beyond, Simon Property, Spirit Airlines, Twitter, Under Armour and More
Thursday's top analyst upgrades and downgrades included Allstate, Bed Bath & Beyond, Simon Property, Spirit Airlines, Twitter and Under Armour.
Lee Jackson
Published:

How Big Is This Setback to Altimmune's COVID-19 Vaccine Candidate?
Altimmune shares dropped on Thursday after the company announced that it had received an update from the FDA regarding its COVID-19 vaccine candidate.
Chris Lange
Published:

Altimmune Takes Next Step With Its COVID-19 Intranasal Vaccine
Altimmune made a step forward on Tuesday with its vaccine candidate for COVID-19. Specifically, the firm entered into a manufacturing agreement the vaccine candidate.
Chris Lange
Published:

What This Capital Injection Means for Altimmune
Altimmune made some progress with its COVID-19 treatment on Monday after it announced some new funding for its trials.
Chris Lange
Published:
Last Updated:

How Coronavirus Stocks Are Handling Monday's Market Meltdown
24/7 Wall St. has tracked some stocks that either are defensive in general or are defying Monday's big drop because they have some aspect of their business that might be immune to daily scares or...
Chris Lange
Published:

What's Next for Altimmune's Influenza Vaccine
Altimmune shares surged on Tuesday following results from its midstage study of a intranasal influenza vaccine candidate.
Chris Lange
Published:
Last Updated: